JNU Biopharmaceutical Group

JNU Biopharmaceutical Group is a prominent Chinese biotechnology enterprise specializing in the development and commercialization of recombinant protein therapeutics, with a core focus on the Fibroblast Growth Factor (FGF) family. Serving as the industrialization platform for the National Engineering Research Center of Genetic Medicine at Jinan University, the group has pioneered the clinical application of FGFs in China. Its portfolio includes several NMPA-approved products such as recombinant human acidic fibroblast growth factor (raFGF) and basic fibroblast growth factor (rbFGF) for wound healing and regenerative medicine. The company's robust R&D pipeline features advanced candidates like KGF-2 for oral mucositis, FGF-21 for metabolic disorders, and FGF-18 for osteoarthritis. Beyond therapeutics, JNU Biopharmaceutical is a major supplier of bioactive ingredients for the high-end medical aesthetics and skincare markets.